We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?
- Authors
Haelewyn, Benoît; Risso, Jean-Jacques; Abraini, Jacques H
- Abstract
Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is 10-fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of 0.9 mg/kg rtPA (the clinical dose in stroke patients). In this study, we compared the effects of these doses on mean time to reperfusion, reperfusion slope, brain infarct volume and edema in a rat model of thrombo-embolic stroke. Our data provide evidence that the dose of 0.9 mg/kg rtPA is as appropriate as that of 10 mg/kg for preclinical stroke studies in rodents.
- Publication
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010, Vol 30, Issue 5, p900
- ISSN
1559-7016
- Publication type
Journal Article
- DOI
10.1038/jcbfm.2010.33